State laws and regulations addressing third-party reimbursement for infertility treatment: implications for cancer survivors

Quinn, Gwendolyn P.; Vadaparampil, Susan T.; Lowrey, Kerri McGowan; Eidson, Shelby Smith; Knapp, Caprice; Bükülmez, Orhan

doi:10.1016/j.fertnstert.2010.05.017

Cited by 47 publications

(35 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the USA, coverage for FP varies by state, with insurance in some states covering initial costs of the harvesting and banking procedure but not always paying the annual storage fee [46,47]. The estimated cost of storing three samples of sperm produced by masturbation for 3 years in a sperm bank in 2006 was close to $1,500 [42].…”

Section: Barriers To Fpmentioning

confidence: 99%

Fertility preservation in patients receiving cyclophosphamide therapy for renal disease

et al. 2014

View full text Add to dashboard Cite

Cyclophosphamide continues to have an important role in the treatment of renal disease, including nephrotic syndrome and lupus nephritis, despite known complications of gonadotoxicity and potential infertility in both male and female patients. It is important that the physician recommending this therapy mitigates the effect of the drug on fertility by adhering to recommendations on dosing limits and offering fertility-preserving strategies. In addition to wellestablished methods, such as sperm banking and embryo cryopreservation, advances in reproductive technology have yielded strategies such as oocyte cryopreservation, resulting in more fertility-preserving options for the pediatric patient. Despite these advances, there continues to be a significant barrier to referral and access to sperm banks and fertility specialists. These issues are further complicated by ethical issues associated with the treatment of pediatric patients. In this review we explore the development of recommended dosing limits and include a discussion of the available fertility-preserving methods, strategies for increasing access to fertility specialists, and the ethical considerations facing the pediatric healthcare provider.

show abstract

Section: Barriers To Fpmentioning

confidence: 99%

Fertility preservation in patients receiving cyclophosphamide therapy for renal disease

et al. 2014

View full text Add to dashboard Cite

show abstract

“…The information provided to pediatric patients the majority do not (15,39,65). In fact, several and their families is also limited by the few fertility authors note that a perception of the high cost of preservation technologies available for prepubertal patients (28).…”

Section: Social Barriers To the Use Ofmentioning

confidence: 99%

“…Furthermore, time policies requiring coverage of fertility preservation and budget restrictions and lack of information lead options for cancer patients before treatment (the pediatric patients and their parents to make same way the other side effects of cancer treatunfounded decisions that can end up affecting the ments are covered), "no state has codified an insurfuture reproductive health of the patient (62). ance mandate that would cover the expenses of a single cancer patient before cancer treatment to preserve his or her fertility" (65). Therefore, the CONCLUSIONS issue of insurance coverage is dependent on the local legislation.…”

Section: Social Barriers To the Use Ofmentioning

confidence: 99%

“…The men of reproductive age are diagnosed with cancer term was coined by Teresa Woodruff from the each year (65), and up to 90% of these people may Oncofertility Consortium at Northwestern Univerbe at risk of losing their fertility after undergoing sity and involves fields such as gynecology, oncolcancer treatment (45, 65). While various fertility ogy, and endocrinology as well as the social sciences preservation methods are available for both male and bioethics (43,84).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Fertility Preservation Technologies for Oncology Patients in the Us: A Review of the Factors Involved in Patient Decision Making

Vindrola‐Padros¹,

Mitu²,

Dyer³

2012

technol innov

View full text Add to dashboard Cite

The field of oncofertility addresses issues of infertility in oncology patients. Even though this field has integrated professionals from multiple disciplines, a significant amount of research still needs to be carried out to understand the factors involved in patients' access to fertility preservation technologies, the worries and concerns of cancer patients and survivors, and the strategies used to deal with fertility transformations. The purpose of this article is to present a review of the existing social research on oncofertility, discuss notable gaps in knowledge, and identify future areas of study. We examine the relationship between common medical treatments used to treat cancer and their effects on fertility; available fertility preservation technologies; the social, political, cultural, and economic factors involved in medical care, patient decision making, and access to technological procedures; and existing guidelines and organizations in the US that focus on patient information and advocacy. This review seeks to encourage researchers to bring patient experience to the forefront of oncofertility research and consider the factors that continue to hinder their access to the technologies required to safeguard their fertility.

show abstract

“…Sperm cryopreservation typically costs $700-900 for the initial collection and $200-400 per year for storage. 25 Embryo cryopreservation can cost up to $5000 for stimulation of the ovaries, $5000-10,000 for egg harvesting, and $5000 for each embryo transfer attempt. 25 Fertile Hope and Livestrong have a Sharing Hope program that aims to arrange for discounted services and donations for eligible patients.…”

Section: Palliative Carementioning

confidence: 99%

Posthumous Reproduction and Palliative Care

Knapp

Quinn

Bower

et al. 2011

Journal of Palliative Medicine

Self Cite

View full text Add to dashboard Cite

Posthumous reproduction is an issue fraught with legal, ethical, religious, and moral debate. The involvement of the hospice and palliative care community in this debate may be peripheral due to the fact that other health care professionals would be actually delivering the services. However, the hospice and palliative care community are more likely to treat patients considering posthumous reproduction as they near the end of their lives. This article provides the hospice and palliative care community with a review of the medical, ethical, and legal considerations associated with posthumous reproduction. Having knowledge of these issues, and a list of available resources, will be useful if hospice and palliative care staff find themselves facing a patient or family that is considering posthumous reproduction.

show abstract

State laws and regulations addressing third-party reimbursement for infertility treatment: implications for cancer survivors

Cited by 47 publications

References 11 publications

Fertility preservation in patients receiving cyclophosphamide therapy for renal disease

Fertility preservation in patients receiving cyclophosphamide therapy for renal disease

Fertility Preservation Technologies for Oncology Patients in the Us: A Review of the Factors Involved in Patient Decision Making

Posthumous Reproduction and Palliative Care

Contact Info

Product

Resources

About